DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Triciribine is an investigational drug.
There have been 5 clinical trials for Triciribine. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2014.
The most common disease conditions in clinical trials are Leukemia, Acute Disease, and Hematologic Neoplasms. The leading clinical trial sponsors are Prescient Therapeutics, Ltd., VioQuest Pharmaceuticals, and National Cancer Institute (NCI).
Recent Clinical Trials for Triciribine
|A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia||Prescient Therapeutics, Ltd.||Phase 1/Phase 2|
|PTX-200 and Carboplatin in Ovarian Cancer||Prescient Therapeutics, Ltd.||Phase 1/Phase 2|
|PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer||National Cancer Institute (NCI)||Phase 1/Phase 2|